- Tytuł:
- Dendritic cell Flt3 - regulation, roles and repercussions for immunotherapy.
- Autorzy:
- Źródło:
- Immunology and cell biology [Immunol Cell Biol] 2021 Oct; Vol. 99 (9), pp. 962-971. Date of Electronic Publication: 2021 Jul 02.
- Typ publikacji:
- Journal Article; Research Support, Non-U.S. Gov't; Review
- Język:
- English
- Imprint Name(s):
-
Publication: 2018- : [Hoboken, NJ] : Wiley
Original Publication: [Adelaide, South Australia] : University of Adelaide, [c1987- - MeSH Terms:
-
Dendritic Cells*
fms-Like Tyrosine Kinase 3*/genetics
Immunologic Factors ; Immunotherapy ; T-Lymphocytes - References:
-
Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 2020; 20: 7-24.
Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137: 1142-1162.
Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol. 2006; 6: 476-483. http://dx.doi.org/10.1038/nri1845.
Miller JC, Brown BD, Shay T, et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol 2012; 13: 888-899.
Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368: 643-648.
Lyman SD, James L, Johnson L, et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 1994; 83: 2795-2801.
Lyman SD, James L, Bos TV, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993; 75: 1157-1167.
Lyman SD, James L, Escobar S, et al. Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs. Oncogene 1995; 10: 149-157.
Chklovskaia E, Jansen W, Nissen C, et al. Mechanism of flt3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesis. Blood 1999; 93: 2595-2604.
Saito Y, Boddupalli CS, Borsotti C, Manz MG. Dendritic cell homeostasis is maintained by nonhematopoietic and T-cell-produced Flt3-ligand in steady state and during immune responses. Eur J Immunol 2013; 43: 1651-1658.
Chklovskaia E, Nissen C, Landmann L, Rahner C, Pfister O, Wodnar-Filipowicz A. Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor γ-chain signaling and inhibited by cyclosporin A. Blood 2001; 97: 1027-1034.
Horiuchi K, Morioka H, Takaishi H, Akiyama H, Blobel CP, Toyama Y. Ectodomain shedding of FLT3 ligand is mediated by TACE. J Immunol 2009; 182: 7408-7414.
Fujita K, Chakarov S, Kobayashi T, et al. Cell-autonomous FLT3L shedding via ADAM10 mediates conventional dendritic cell development in mouse spleen. Proc Natl Acad Sci USA 2019; 116: 14714-14723.
Carotta S, Dakic A, D’Amico A, et al. The transcription factor PU.1 controls dendritic cell development and Flt3 cytokine receptor expression in a dose-dependent manner. Immunity 2010; 32: 628-641.
Gwin K, Frank E, Bossou A, Medina KL. Hoxa9 regulates Flt3 in lymphohematopoietic progenitors. J Immunol 2010; 185: 6572-6583.
Gwin KA, Shapiro MB, Dolence JJ, Huang ZL, Medina KL. Hoxa9 and Flt3 signaling synergistically regulate an early checkpoint in lymphopoiesis. J Immunol 2013; 191: 745-754.
Volpe G, Walton DS, Del Pozzo W, et al. C/EBPα and MYB regulate FLT3 expression in AML. Leukemia 2013; 27: 1487-1496.
Volpe G, Clarke M, Garcìa P, et al. Regulation of the flt3 gene in haematopoietic stem and early progenitor cells. PLoS One 2015; 10: 1-18.
Kato T, Sakata-Yanagimoto M, Nishikii H, et al. Hes1 suppresses acute myeloid leukemia development through FLT3 repression. Leukemia 2015; 29: 576-585.
De Obaldia ME, Bell JJ, Wang X, et al. T cell development requires constraint of the myeloid regulator C/EBP-α by the Notch target and transcriptional repressor Hes1. Nat Immunol 2013; 14: 1277-1284.
Holmes ML, Carotta S, Corcoran LM, Nutt SL. Repression of Flt3 by Pax5 is crucial for B-cell lineage commitment. Genes Dev 2006; 20: 933-938.
Lyman SD, James L, Zappone J, Sleath PR, Beckmann MP, Bird T. Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. Oncogene 1993; 8: 815-822.
Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy VC. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996; 88: 3383-3390.
Zhang S, Broxmeyer HE. p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. Biochem Biophys Res Commun 1999; 254: 440-445.
Durai V, Bagadia P, Briseño CG, et al. Altered compensatory cytokine signaling underlies the discrepancy between Flt3-/- and Flt3l-/- mice. J Exp Med 2018; 215: 1417-1435.
Zhang S, Mantel C, Broxmeyer HE. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J Leukoc Biol 1999; 65: 372-380.
Sathaliyawala T, O’Gorman WE, Greter M, et al. Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity 2010; 33: 597-606.
Laouar Y, Welte T, Fu XY, Flavell RA. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity 2003; 19: 903-912.
Onai N, Obata-Onai A, Tussiwand R, Lanzavecchia A, Manz MG. Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development. J Exp Med 2006; 203: 227-238.
Lavagna-Sévenier C, Marchetto S, Birnbaum D, Rosnet O. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 1998; 12: 301-310.
Rathinam C, Thien CBF, Flavell RA, Langdon WY. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling. Cancer Cell 2010; 18: 341-352.
Scheffler JM, Sparber F, Tripp CH, et al. LAMTOR2 regulates dendritic cell homeostasis through FLT3-dependent mTOR signalling. Nat Commun 2014; 5: 5138.
Naik SH, Perié L, Swart E, et al. Diverse and heritable lineage imprinting of early haematopoietic progenitors. Nature 2013; 496: 229-232.
D’Amico A, Wu L. The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J Exp Med 2003; 198: 293-303.
Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med 2003; 198: 305-313.
Audiger C, Lesage S. FLT3 ligand is dispensable for the final stage of Type 1 conventional dendritic cell differentiation. J Immunol 2020; 205: 2117-2127.
Ginhoux F, Liu K, Helft J, et al. The origin and development of nonlymphoid tissue CD103+ DCs. J Exp Med 2009; 206: 3115-3130.
Maraskovsky E, Brasel K, Teepe MK, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-1962.
Waskow C, Liu K, Darrasse-Jèze G, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol 2008; 9: 676-683.
Maraskovsky E, Daro E, Roux E, et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000; 96: 878-884.
Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995; 3: 147-161.
McKenna HJ, Stocking KL, Miller RE, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000; 95: 3489-3497.
Swee LK, Bosco N, Malissen B, Ceredig R, Rolink A. Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment. Blood 2009; 113: 6277-6287.
Darrasse-Jèze G, Deroubaix S, Mouquet H, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med 2009; 206: 1853-1862.
Klein O, Ebert LM, Zanker D, et al. Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects. Eur J Immunol 2013; 43: 533-539.
Lau CM, Nish SA, Yogev N, Waisman A, Reiner SL, Reizis B. Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses. J Exp Med 2016; 213: 415-431.
Guermonprez P, Helft J, Claser C, et al. Inflammatory Flt3L is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nat Med 2013; 19: 730-738.
Barry KC, Hsu J, Broz ML, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med 2018; 24: 1178-1191.
Salmon H, Idoyaga J, Rahman A, et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 2016; 44: 924-938.
Broz ML, Binnewies M, Boldajipour B, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014; 26: 638-652.
Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T Cell therapy. Cancer Cell 2017; 31: 711-723. e4.
Hammerich L, Marron TU, Upadhyay R, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med 2019; 25: 814-824.
Lai J, Mardiana S, House IG, et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat Immunol 2020; 21: 914-926.
Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 1998; 58: 380-383.
Sánchez-Paulete AR, Cueto FJ, Martínez-López M, et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov 2016; 6: 71-79.
Anandasabapathy N, Feder R, Mollah S, et al. Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. J Exp Med 2014; 211: 1875-1891.
Bedoui S, Prato S, Mintern J, et al. Characterization of an immediate splenic precursor of CD8+ dendritic cells capable of inducing antiviral T cell responses. J Immunol 2009; 182: 4200-4207.
Beshara R, Sencio V, Soulard D, et al. Alteration of Flt3-Ligand-dependent de novo generation of conventional dendritic cells during influenza infection contributes to respiratory bacterial superinfection. PLoS Pathog 2018; 14: e1007360.
Saevarsdottir S, Olafsdottir TA, Ivarsdottir EV, et al. FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease. Nature 2020; 584. https://doi.org/10.1038/s41586-020-2436-0.
Dehlin M, Bokarewa M, Rottapel R, et al. Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis. PLoS One 2008; 3: e3633. - Contributed Indexing:
- Keywords: Flt3; dendritic cells; immunity
- Substance Nomenclature:
-
0 (Immunologic Factors)
EC 2.7.10.1 (fms-Like Tyrosine Kinase 3) - Entry Date(s):
- Date Created: 20210607 Date Completed: 20211025 Latest Revision: 20211025
- Update Code:
- 20240104
- DOI:
- 10.1111/imcb.12484
- PMID:
- 34097779
- Czasopismo naukowe
Menu główne
Wyszukiwarka
Treść główna
